ArticleScientific reports2022
Characterization of antibiotic-resistance traits in Akkermansia muciniphila strains of human origin.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Impact of the anti-inflammatory macrolide glasmacinal on the gut microbiota of healthy adults: an open-label trial.Nature communications · 2026Article
- Review
- Akkermansia muciniphila-derived 5-MIAA blunts colitis-associated tumorigenesis by modulating colonic SLC26A3/pSTAT3 signaling.NPJ biofilms and microbiomes · 2026Article
- Navigating the duality of Akkermansia muciniphila.Nature microbiology · 2026Review
- Strain-Specific Safety Evaluation ofFood science & nutrition · 2025Article
- Evaluating Effects of Antibiotics Across Preclinical Models of the Human Gastrointestinal Microbiota.MicrobiologyOpen · 2025Article
- Akkermansia muciniphila: promises and pitfallsfor next-generation beneficial microorganisms.Archives of microbiology · 2025Review
- Genomic Face-off: AnCurrent genomics · 2025Article
- Lack of genotoxicity and subchronic toxicity in safety assessment studies ofToxicology reports · 2024Article
- Characterization and Preliminary Safety Evaluation ofFoods (Basel, Switzerland) · 2024Article
- Function and therapeutic prospects of next-generation probioticFrontiers in microbiology · 2024Review
- Whole-genome sequencing and genomic analysis of fourFrontiers in microbiology · 2024Article
- Review
- Biotechnological Potential and Safety Evaluation of Dextran- and Riboflavin-ProducingFoods (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Akkermansia muciniphila, a commensal bacterium commonly found in healthy gut microbiota, is widely considered a next-generation beneficial bacterium candidate to improve metabolic and inflammatory disorders. Recently the EFSA's Panel on Nutrition, Novel food, and Food Allergens has declared that pasteurized A. muciniphila DSM 22959
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.